WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement of GMP manufacturing at its state-of-the-art commercialization facilities, XBCM2 and XDP2, located in Wuxi. This development is anticipated to double the company’s manufacturing capacities, enhancing its capabilities in the biopharmaceutical sector.
Facilities and Production Lines
The new 7000 sq.m facilities are equipped with dual functional production lines, including XBCM2 for the manufacturing of drug conjugate intermediates and raw materials, and XDP2 for drug conjugates formulations. In addition to production, the facilities house product testing and commercial packaging lines, ensuring a comprehensive approach to biopharmaceutical manufacturing.
Significance of the Expansion
The expansion of WuXi XDC’s manufacturing capabilities with the initiation of GMP manufacturing at XBCM2 and XDP2 is a strategic move that aligns with the growing demand for biopharmaceuticals. It underscores the company’s commitment to providing high-quality products and services to its global clientele.-Fineline Info & Tech
